UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT
TO RULE 13A-16 OR 15D-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of: November, 2004
Commission File Number: 000-50393
NEUROCHEM INC.
275 Armand-Frappier Boulevard
Laval, Quebec
H7V 4A7
Indicate by check mark whether the registrant files or will file annual reports
under cover of Form 20-F or Form 40-F. Form 20-F [ ] Form 40-F [X]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1):
Yes [ ] No [X]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7):
Yes [ ] No [X]
Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g-3 under the Securities Exchange Act of 1934.
Yes [ ] No [X]
If "Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b):
SIGNATURES:
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
NEUROCHEM INC.
November 9, 2004
By: /s/ David Skinner
-----------------------------------
David Skinner
Director, Legal Affairs,
General Counsel and Corporate Secretary
[LOGO NEUROCHEM] NEUROCHEM INC.
275 Armand-Frappier Blvd.
Laval, Quebec, Canada H7V 4A7
- --------------------------------------------------------------------------------
FOR FURTHER INFORMATION, PLEASE CONTACT:
Lise Hebert, PhD Tel: (450) 680-4572
Vice President, Corporate Communications lhebert@neurochem.com
NEUROCHEM TO PRESENT AT
CIBC WORLD MARKETS 15TH ANNUAL HEALTHCARE CONFERENCE
MONTREAL, CANADA, NOV. 8, 2004 - Neurochem Inc. (NASDAQ: NRMX; TSX: NRM)
announced today that on Tuesday, Nov. 9, 2004, Francesco Bellini, PhD, Chairman
and CEO, will present Neurochem's overall strategy and progress to date at the
CIBC World Markets Fifteenth Annual Healthcare Conference to be held at the
Plaza Hotel in New York City. The presentation will take place at 8:30 A.M. ET.
The corporate presentation will be available on the Company's website at
http://www.neurochem.com/Investor.htm#Presentation.
An audio webcast of Neurochem's presentation can also be accessed at
http://www.veracast.com/webcasts/cibcwm/healthcare04/13202272.cfm
This webcast will be available for 30 days through to December 10, 2004.
ABOUT NEUROCHEM
Neurochem is focused on the development and commercialization of innovative
therapeutics for neurological disorders. The Company's pipeline of proprietary,
disease-modifying oral products addresses critical unmet medical needs.
Fibrillex(TM), designated as an orphan drug and as a Fast Track Product
candidate, is also part of a Continuous Marketing Applications Pilot 2 program
and is currently in a Phase II/III clinical trial for the treatment of Amyloid A
Amyloidosis. Alzhemed(TM), for the treatment of Alzheimer's Disease, is in a
Phase III clinical trial and Cerebril(TM), for the prevention of Hemorrhagic
Stroke caused by Cerebral Amyloid Angiopathy, has completed a Phase II clinical
trial.
TO CONTACT NEUROCHEM
For additional information on Neurochem and its drug development programs,
please call the North American toll-free number 1 877 680-4500 or visit our Web
Site at: www.neurochem.com.
Certain statements contained in this news release, other than statements of fact
that are independently verifiable at the date hereof, may constitute
forward-looking statements. Such statements, based as they are on the current
expectations of management, inherently involve numerous risks and uncertainties,
known and unknown, many of which are beyond Neurochem's control. Such risks
include but are not limited to: the impact of general economic conditions,
general conditions in the pharmaceutical industry, changes in the regulatory
environment in the jurisdictions in which Neurochem does business, stock market
volatility, fluctuations in costs, and changes to the competitive environment
due to consolidation, as well as other risks disclosed in public filings of
Neurochem. Consequently, actual future results may differ materially
- 2 -
from the anticipated results expressed in the forward-looking statements. The
reader should not place undue reliance on, if any, the forward-looking
statements included in this news release. These statements speak only as of the
date made and Neurochem is under no obligation and disavows any intention to
update or revise such statements as a result of any event, circumstances or
otherwise.